Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Concurrent loss of TP53 and CDKN2A with tetraploidy predicts richter transformation and poor prognosis in chronic lymphocytic leukemia

Blood (2025) 146 (Supplement 1): 2133.

https://doi.org/10.1182/blood-2025-2133

Published: 2025

Journal Articles

A phase II multi-institutional Study evaluating the safety and efficacy of the combination of lisocabtagene maraleucel and zanubrutinib in patients with richter transformation

Aseel Alsouqi, Ying Huang, Lindsey Rike, Lillian Dweik, Swetha Hinton, Mollie Moran, Mark Reid, Corinne Hoffman, Cara Grantier, Margaret Lucas, Amneet Bajwa, Seema Bhat, Michael Grever, Kerry Rogers, Harsh Shah, Jennifer Woyach, Adam Kittai

Blood (2025) 146 (Supplement 1): 1953.

https://doi.org/10.1182/blood-2025-1953

Published: 2025

Journal Articles

MAP2K1 and MAP2K2 genes alterations in hairy cell leukemia and hairy cell leukemia variant.

Evgeny Arons, Tai Chin-Hsein, Liu Yuelin, Chi-Ping Day, Christopher Oakes, Seema Bhat, Michael Grever, Kerry Rogers, Mark Raffeld, Liqiang Xi, Hong Zhou, Mory Gould, Arieh Fischthal, Isaac Shpilman, Hao-Wei Wang, Constance Yuan, Cenk Sahinalp, Robert Kreitman

Blood (2025) 146 (Supplement 1): 3532.

https://doi.org/10.1182/blood-2025-3532

Published: 2025

Journal Articles

Non-V600E BRAF mutations and treatment for hairy cell leukemia

Evgeny Arons, Chin-Hsien Tai, Joshi Suraj, Yuelin Liu, Chi-Ping Day, Mark Raffeld, Liqiang Xi, Hong Zhou, Mory Gould, Isaac Shpilman, Cristopher C. Oakes, Seema Bhat, Michael Grever, Daniel Jones, Kerry Rogers, Hao-Wei Wang, Constance M. Yuan, Cenk Sahinalp, Robert J. Kreitman

Blood (2025) 145 (17): 1957–1961.

https://doi.org/10.1182/blood.2024026894

Published: 2025

Includes: Supplemental data

Journal Articles

Ventricular arrhythmias and sudden death events following acalabrutinib initiation

Seema A. Bhat, John Gambril, Leylah Azali, Sunnia T. Chen, Lindsay Rosen, Marilly Palettas, Tracy E. Wiczer, Sujay Kalathoor, Qiuhong Zhao, Kerry A. Rogers, Adam Kittai, Michael Grever, Farrukh Awan, Patrick Ruz, John C. Byrd, Jennifer Woyach, Daniel Addison

Blood (2022) 140 (20): 2142–2145.

https://doi.org/10.1182/blood.2022016953

Published: 2022

Includes: Supplemental data

Journal Articles

Combination Chemoimmunotherapy with Pentostatin, Cyclophosphamide and Rituximab Shows Significant Clinical Activity with Low Accompanying Toxicity in Previously Untreated B-Chronic Lymphocytic Leukemia.

Neil Kay, MD, Susan Geyer, PhD, Timothy Call, MD, Tait Shanafelt, MD, Clive Zent, MD, Diane Jelinek, PhD, Renee Tschumper, Nancy Bone, Gordon Dewald, PhD, Thomas Lin, PhD, Nyla Heerema, PhD, Laura Smith, Michael Grever, MD, John Byrd, MD

Blood (2006) 108 (11): 35.

https://doi.org/10.1182/blood.V108.11.35.35

Published: 2006

Journal Articles

Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance

Ping-Hui Tseng, Ho-Pi Lin, Jiuxiang Zhu, Kuen-Feng Chen, Erinn M. Hade, Donn C. Young, John C. Byrd, Michael Grever, Kara Johnson, Brian J. Druker, Ching-Shih Chen

Blood (2005) 105 (10): 4021–4027.

https://doi.org/10.1182/blood-2004-07-2967

Published: 2005

Journal Articles

A novel celecoxib derivative, OSU03012, induces cytotoxicity in primary CLL cells and transformed B-cell lymphoma cell line via a caspase- and Bcl-2–independent mechanism

Amy J. Johnson, Lisa L. Smith, Jiuxiang Zhu, Nyla A. Heerema, Sara Jefferson, Andrew Mone, Michael Grever, Ching-Shih Chen, John C. Byrd

Blood (2005) 105 (6): 2504–2509.

https://doi.org/10.1182/blood-2004-05-1957

Published: 2005

Journal Articles

A Novel Celecoxib Derivative, OSU03012, Induces Cytotoxicity in Primary CLL Cells and Transformed B-Cell Lymphoma Via a Caspase and Bcl-2 Independent Mechanism.

Amy Johnson, PhD, Lisa Smith, Jiuxiang Zhu, Nyla Heerema, PhD, Sara Guster, Andrew Mone, MD, PhD, Michael Grever, MD, Ching-Shih Chen, PhD, John Byrd, MD

Blood (2004) 104 (11): 3471.

https://doi.org/10.1182/blood.V104.11.3471.3471

Published: 2004

Journal Articles

Pharmacodynamics provide critical insight in drug development

Michael Grever

Blood (2004) 103 (10): 3614.

https://doi.org/10.1182/blood-2004-03-0988

Published: 2004

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Concurrent loss of TP53 and CDKN2A with tetraploidy predicts richter transformation and poor prognosis in chronic lymphocytic leukemia

A phase II multi-institutional Study evaluating the safety and efficacy of the combination of lisocabtagene maraleucel and zanubrutinib in patients with richter transformation

MAP2K1 and MAP2K2 genes alterations in hairy cell leukemia and hairy cell leukemia variant.

Non-V600E BRAF mutations and treatment for hairy cell leukemia

Ventricular arrhythmias and sudden death events following acalabrutinib initiation

Combination Chemoimmunotherapy with Pentostatin, Cyclophosphamide and Rituximab Shows Significant Clinical Activity with Low Accompanying Toxicity in Previously Untreated B-Chronic Lymphocytic Leukemia.

Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance

A novel celecoxib derivative, OSU03012, induces cytotoxicity in primary CLL cells and transformed B-cell lymphoma cell line via a caspase- and Bcl-2–independent mechanism

A Novel Celecoxib Derivative, OSU03012, Induces Cytotoxicity in Primary CLL Cells and Transformed B-Cell Lymphoma Via a Caspase and Bcl-2 Independent Mechanism.

Pharmacodynamics provide critical insight in drug development

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only